Wave Life Sciences Plans For Two-Year Registrational Trial For WVE-006 To Treat Alpha-1 Antitrypsin Deficiency

Wave Life Sciences, Inc. (Nasdaq: WVE) has announced plans for a two-year registrational trial for its investigational drug WVE-006, aimed at treating alpha-1 antitrypsin deficiency (AATD). The company has aligned with the FDA on key aspects of the trial, which will include a one-year interim analysis for potential accelerated approval based on AATD biomarkers. The FDA has also approved the use of Wave's current LC-MS assay to measure relevant proteins for the registrational program.